SCHEMBL10187448

SCHEMBL10187448

CN(C)C(=O)Sc1ccc(Cc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
PLA2G10 O15496 1/20 0.44
PLA2G2A P14555 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CALM1 P0DP23 1/20 0.41
LTA4H P09960 6/20 0.40
HNF4A P41235 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TBXA2R P21731 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
PTGDR Q13258 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7776861 0.83 ALDH1A1 (0.45) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL20244667 0.81 ALDH1A1 (0.53) LMNAALDH1A1NPC1RAB9AKMT2A
SCHEMBL6541372 0.81 CA2 (0.47) LMNAALDH1A1
SCHEMBL10187470 0.80 LMNA (0.58) LMNAPLA2G10PLA2G2AALDH1A1CALM1
SCHEMBL8164406 0.80 ALDH1A1 (0.44) LMNAALDH1A1NPC1MEN1KMT2A
SCHEMBL31260342 0.79 HRH3 (0.47) ALDH1A1RAB9AMEN1KMT2ASLC6A2
SCHEMBL2578840 0.79 ALDH1A1 (0.46) ALDH1A1
SCHEMBL5574240 0.79 ALDH1A1 (0.46) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL1602482 0.77 PLA2G10 (0.41) LMNAPLA2G10PLA2G2AALDH1A1LTA4H
SCHEMBL28861673 0.77 HPGD (0.55) LMNAALDH1A1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093287-B2 Inhibitors of matrix metalloproteinases UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-01-10 US disclosed
US-20110293643-A1 COMPOUNDS AND METHODS FOR INHIBITING MMP2 AND MMP9 INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2011-12-01 US disclosed
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES NOTRE DAME UNIVERSITY (US) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110293643-A1 COMPOUNDS AND METHODS FOR INHIBITING MMP2 AND MMP9 MMP9, MMP26, MMP2 LMNA 3053/4885PLA2G10 1452/4885PLA2G2A 1179/4885
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES MMP9, MMP1, MMP2 LMNA 358/4885PLA2G10 744/4885PLA2G2A 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.